Literature DB >> 19262027

Fibrocartilaginous embolism of the spinal cord diagnosed by characteristic clinical findings and magnetic resonance imaging in 26 dogs.

Yuya Nakamoto1, Tsuyoshi Ozawa, Kengo Katakabe, Koichi Nishiya, Nobuhiro Yasuda, Tadahisa Mashita, Yutaka Morita, Munekazu Nakaichi.   

Abstract

Fibrocartilaginous embolism (FCE) is a disorder of acute onset that presents with nonprogressive ataxia. We performed a retrospective examination of FCE of the spinal cord diagnosed by characteristic clinical findings and magnetic resonance imaging (MRI) in 26 dogs. In the present study, treatment consisting of physiotherapy alone, or this in combination with corticosteroid administration, was initiated immediately following diagnosis of FCE. Age at onset and the gender ratio in the present study closely correlated with those previously reported. In the present study, 88% of the dogs that developed FCE were small- to medium-sized, which is different from previously reported studies. There is a possibility that FCE also develops relatively frequently in small- to medium-sized dogs. No significant difference was observed between the physiotherapy alone and the physiotherapy and corticosteroids groups of dogs. FCE development has been reported predominantly at the vertebral levels C6-T2 and L4-S3 and less frequently at C1-5 and T3-L3. However, in the present study, FCE developed predominantly at T3-L3. FCE developed at T3-L3 or C1-5 in 69% of the cases in the present study, suggesting that there is relatively frequent development of FCE at these vertebral levels. The recovery time of T3-L3 was the shortest (10.2 +/- 7.4 days), and that of C1-5 was next-shortest (15.8 +/- 5.4) in this study. This suggested the possibility that the detection ratio of cases was low, because the symptoms in cases of FCE that has developed in C1-5 and T3-L3 would have improved before inspection in the secondary institution, where the MRI and diagnosis were performed.

Entities:  

Mesh:

Year:  2009        PMID: 19262027     DOI: 10.1292/jvms.71.171

Source DB:  PubMed          Journal:  J Vet Med Sci        ISSN: 0916-7250            Impact factor:   1.267


  7 in total

1.  Magnetic resonance imaging muscle lesions in presumptive canine fibrocartilaginous embolic myelopathy.

Authors:  Sabrina M Martens; Stephanie G Nykamp; Fiona M K James
Journal:  Can Vet J       Date:  2018-12       Impact factor: 1.008

2.  Presumptive fibrocartilaginous embolic myelopathy in a pot-bellied pig.

Authors:  Shannon Darby; Diego E Gomez; Kallie Hobbs; Sheila Carrera-Justiz; Federico Vilaplana Grosso; Robert MacKay
Journal:  Can Vet J       Date:  2021-02       Impact factor: 1.008

3.  Percutaneous transplantation of human umbilical cord-derived mesenchymal stem cells in a dog suspected to have fibrocartilaginous embolic myelopathy.

Authors:  Wook-Hun Chung; Seon-Ah Park; Jae-Hoon Lee; Dai-Jung Chung; Wo-Jong Yang; Eun-Hee Kang; Chi-Bong Choi; Hwa-Seok Chang; Dae-Hyun Kim; Soo-Han Hwang; Hoon Han; Hwi-Yool Kim
Journal:  J Vet Sci       Date:  2013-06-28       Impact factor: 1.672

4.  Diffusion-Weighted Imaging Findings of Ischemic Spinal Injury in a Chondrodystrophic Dog With Fibrocartilaginous Embolism.

Authors:  Taesik Yun; Kang-Il Lee; Yoonhoi Koo; Hakhyun Kim; Dongwoo Chang; Chulhyun Lee; Mhan-Pyo Yang; Byeong-Teck Kang
Journal:  Front Vet Sci       Date:  2020-12-10

Review 5.  Overview of the Current Literature on the Most Common Neurological Diseases in Dogs with a Particular Focus on Rehabilitation.

Authors:  Giuseppe Spinella; Piera Bettella; Barbara Riccio; Samuel Okonji
Journal:  Vet Sci       Date:  2022-08-13

6.  Magnetic resonance imaging (MRI) spinal cord and canal measurements in normal dogs.

Authors:  S Hecht; M M Huerta; R B Reed
Journal:  Anat Histol Embryol       Date:  2013-03-15       Impact factor: 1.114

7.  Magnetic resonance imaging features of dogs with incomplete recovery after acute, severe spinal cord injury.

Authors:  Melissa J Lewis; Eli B Cohen; Natasha J Olby
Journal:  Spinal Cord       Date:  2017-10-23       Impact factor: 2.772

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.